摘要
目的:探讨阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效。方法:选取2014年2月至2017年2月潜江市中心医院收治的绝经后骨质疏松症患者80例作为研究对象,以随机数字表法分为观察组和对照组,每组40例。对照组患者给予碳酸钙D3片,观察组患者给予阿仑膦酸钠片。对比观察两组患者的临床疗效、骨密度、血骨钙素、尿Ⅰ型胶原氨基末端肽/肌酐(NTX/Cr)及不良反应发生情况的差异。结果:观察组患者的总有效率为92.50%(37/40),明显高于对照组的82.50%(33/40),差异有统计学意义(P<0.05);治疗后,两组患者各部位骨密度均较治疗前明显改善,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);治疗后,观察组患者血骨钙素和尿NTX/Cr明显优于治疗前及对照组治疗后,差异均有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为2.50%(1/40)、5.00%(2/40),差异无统计学意义(P>0.05)。结论:阿仑膦酸钠治疗绝经后骨质疏松症的疗效显著,可明显改善患者骨密度,且安全性高。
OBJECTIVE： To probe into the clinical efficacy of alendronate in treatment of postmenopausal osteoporosis. METHODS： 80 patients with postmenopausal osteoporosis admitted into Qianjiang Central Hospital from Feb. 2014 to Feb. 2017 were selected and divided into observation group and control group via random number table,with 40 cases in each. The control group was treated with Calcium carbonate D3 tablets,while the observation group was given Alendronate tablets. Differences in clinical efficacy,bone mineral density（ BMD）,blood osteocalcin,urine NTX/Cr and incidences of adverse drug reactions between two groups were observed and compared. RESULTS： The total effective rate of observation group was 92. 50%（ 37/40）,which was significantly higher than that of the control group（ 82. 50%,33/40）,with statistically significant difference（ P〈0. 05）; after treatment,the BMD at each part in both group were significantly improved,that of observation group was significantly better than the control group,with statistically significant difference（ P〈0. 05）; after treatment,the blood osteocalcin and urine NTX/Cr of observation group were significantly better than those of before treatment and the control group,with statistically significant differences（ P〈0. 05）; the incidences of adverse drug reactions of observation group and control group were respectively 2. 50%（ 1/40） and 5. 00%（ 2/40）,the difference had no statistical significance（ P〈0. 05）.CONCLUSIONS： The efficacy of alendronate in treatment of postmenopausal osteoporosis is remarkable,which can significantly improve patients＇ BMD,with high safety.
作者
彭冲
王运涛
刘兴邦
秦为
PENG Chong, WANG Yuntao, LIU Xingbang, QIN Wei(Dept. of Orthopedics, Qianjiang Central Hospital, Hubei Qianjiang 433100, Chin)
出处
《中国医院用药评价与分析》
2018年第5期600-602,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
绝经后
骨质疏松症
阿仑膦酸钠
骨密度
Postmenopausal
Osteoporosis
Alendronate
Bone mineral density
